Antiretroviral News and Research

RSS

Proposed intellectual property agreement between E.U., India could affect generic drug exports, advocacy groups say

The Independent examines how "the cheap supply of antiretroviral drugs to people with AIDS across the world could be choked by an 'intellectual property' deal ... being negotiated on Friday at the 12th E.U.-India summit in New Delhi between the President of the European Commission, José Manuel Barroso, and the Indian Prime Minister Dr. Manmohan Singh."

13 Feb 2012

Important to include men in HIV prevention, treatment programs

While a focus on HIV prevention and treatment among women and children has reduced infection rates among these populations, "men have received considerably less attention in the epidemic and receive less targeted HIV prevention and treatment programs," Edward Mills of the University of Ottawa and colleagues write in a PLoS Medicine essay, adding "Targeting men in prevention and treatment ... may have a large impact on mortality, new infections, and the economic impact of HIV/AIDS in Africa."

9 Feb 2012

Forum for Collaborative HIV Research suggests new approach for conducting Phase 3 HIV clinical trials

As the war on HIV/AIDS begins its fourth decade, medical researchers, pharmaceutical manufacturers, patient advocates and government regulators face a new and unexpected scientific challenge: how to demonstrate the safety and efficacy of promising new antiretroviral drugs when the two traditional study designs – the superiority trial and the non-inferiority trial – are no longer useful in showing improvements in both "treatment experienced" patients and those who have never received drug therapy (treatment-naive patients).

7 Feb 2012

Antiretroviral therapy does not increase severity of psychiatric disorders

A study of more than 300 children and adolescents with human immunodeficiency virus (HIV) revealed no association between specific antiretroviral therapy and the severity of psychiatric disorders.

7 Feb 2012

Supporting scientific evidence under PEPFAR to end AIDS

On Wednesday, several HIV experts spoke at a Capitol Hill briefing "supporting the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program's reliance on scientific evidence to drive its work to end AIDS," the Center for Global Health Policy's "Science Speaks" blog reports.

7 Feb 2012

Doctors, NPs often issue orders to HIV patients to maintain adherence- Problem solving rare

Take your medicine, Doctor's orders. It's a simple idea that may seem especially obvious when the pills are the antiretroviral (ARV) drugs that add decades to the lives of HIV-positive patients.

3 Feb 2012

CDC models show scaling up ART for HIV treatment can save money over time

During a webinar Thursday hosted by the Health Global Access Project, AVAC, and amfAR, John Blandford, chief of CDC's Division of Global HIV/AIDS Health Economics, Systems and Integration Branch, presented findings showing "that scaling up antiretroviral therapy (ART) for HIV/AIDS treatment and prevention in the developing world not only saves lives, but saves money too," the Center for Global Health Policy's "Science Speaks" blog reports.

31 Jan 2012

Study explores links between antiretroviral prophylaxis, cleft lip and palate

HIV-positive mothers have been able to guard against transmitting the disease to their babies by taking antiretroviral drugs during pregnancy. Although the drugs prevent children from being born with HIV, they could cause birth defects, such as cleft lip and palate. A new study explores any links between antiretroviral prophylaxis and cleft lip and palate.

27 Jan 2012

MSF warns about lack of access to antiretroviral treatment in DRC, urges government, donor action

"Eighty-six percent of HIV-positive people in the Democratic Republic of Congo [DRC] have no access to antiretrovirals, medical charity Doctors Without Borders said Wednesday," calling the "conditions of access to care for people living with HIV/AIDS ... catastrophic," Agence France-Presse reports.

27 Jan 2012

Universal access to HIV treatment can be achieved

"Thirty years after AIDS made its deadly debut, a future without the disease is finally within reach," a Boston Globe editorial states, adding, "But just as science is on the verge of winning the battle, financial resources and political will are flagging."

25 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Aspirin may benefit HIV-infected women at risk of cervical cancer

Research conducted by NewYork-Presbyterian Hospital/Weill Cornell Medical Center global health investigators and cancer specialists in New York, Qatar and Haiti suggests that aspirin should be evaluated for its ability to prevent development of cervical cancer in HIV-infected women.

19 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

Study confirms condom use reduces risk of HIV infection by 78%

The level of HIV-1 in the blood of an HIV-infected partner is the single most important factor influencing risk of sexual transmission to an uninfected partner, according to a multinational study of heterosexual couples in sub-Saharan Africa.

12 Jan 2012

Concerns over using ARV therapy as prevention strategy

PSI's "Healthy Lives" blog reviews a recent Science magazine article written by James Shelton of USAID's Bureau of Global Health in which he raises concerns about the use of antiretroviral drugs (ARVs) as a prevention strategy.

10 Jan 2012

FDA approval of raltegravir offers new weapon to treat HIV infection in children

For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.

7 Jan 2012

J&J will not join Medicines Patent Pool; Company's pharma head says mechanism could 'cause disaster'

Pharmaceutical company "Johnson & Johnson has rejected calls to offer patent rights on its HIV medicines to generic drug companies through a" Medicines Patent Pool, created to promote low-cost antiretroviral drugs in low-income countries and the development of new drug combinations and formulations, the Financial Times reports.

4 Jan 2012

FDA accepts Gilead's Quad HIV regimen NDA for review

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Quad, a complete single-tablet HIV regimen containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.

26 Dec 2011

Science names HIV prevention trial as '2011 Breakthrough of the Year'

"The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID)," which found that early treatment with antiretroviral drugs (ARVs) reduced the risk of transmission among sero-discordant partners by 96 percent, as the "2011 Breakthrough of the Year," an NIH press release states (12/22).

23 Dec 2011

ARV drugs can prevent transmission of HIV

The finding of a team of researchers - including several members from Johns Hopkins - that HIV treatment with antiretroviral drugs (ARVs) can actually prevent transmission of the virus from an infected person to his or her uninfected partner has been named "Breakthrough of the Year" for 2011 by the journal Science.

23 Dec 2011